each: group (A) received 5 mg LE daily & CE 0.5 mg once weekly from first day of menstrual cycle for 6 weeks. Those in group (B) were prescribed only CE for the same dose & duration of trial. Regular follow-up visits were arranged, and changes in uterine & myoma size, volume and number were recorded at each visit for all patients. Adverse effects were recorded if any. Data analyzed and P-value considered to be significant if < 0.05. All analyses were performed using SPSS software. RESULTS: Treatments well tolerated in both groups with minor side effects. Five patients lost during follow-up period, three from (A) & two from (B) groups. Compared with baseline values, mean uterine volume was reduced significantly (P <0.05) in both groups and with significant difference between groups, more in group (A) than (B) (P <0.016). Total number of myomas was reduced significantly in both groups (P < 0.023). Group (A) patients expressed more myoma shrinkage in comparison to those in group (B) (P < 0.05). Reduction rate of tumor nodule varied from 43-78% in (A) group, while that in group (B) was between 38 to 58%. One patient in (A) group discontinued treatment because of headache, none in the other group. CONCLUSIONS: Combination of LE and CE in management of uterine myomas is safe and more effective than CE alone, leading to symptomatic improvements, and might be considered for short term treatments before surgery along with the opportunity to preserve fertility. References: A.M. Elbareg et al: (Effectiveness of dopamine agonist, Cabergoline (Dostinex), treatment on uterine myoma regression in comparison to effect of gonadotrophin-releasing hormone analogue (Zoladex). Fertility and Sterility,